Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Australian Shares Fall as Westpac Slides, Miners Gain Ahead of RBA Decision 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
US Stock Futures Flat as Iran Strait of Hormuz Demands Fuel Oil Concerns 
Asian Stocks Cautious Ahead of US Jobs Data as Oil Rises 
Gold Prices Surge 7% as Dollar Falls, Fed Rate Hike Bets Ease 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
BOJ Signals Faster Rate Hikes as Inflation Risks Raise September Move Odds 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Philippine GDP Growth Slows to 2.3% in Q2 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist 
Lotte Corporation recently formed Lotte Biologics as its newest business unit to venture further into the bio business sector. As the new division starts to operate independently, the company assigned an executive to lead the new team.
According to The Korea Herald, Lotte chose a former Samsung Biologics executive, Lee Won Jik, to be Lotte Biologics’ chief executive officer. He was only given the role of CEO now, but he actually Lotte Corporation in August of last year. Prior to his move, Lee worked as the head of Samsung Biologics’ drug business unit.
Lotte Holdings announced last week that it had completed the registration of Lotte Biologics with a starting capital of KRW1 billion or around $790,000. Lotte Biologics is now in charge of the company’s new bio business, and key executives were already appointed as well. An official at Lotte Holdings said that its bio unit and its new CEO will be formally introduced at the Bio International Convention that will start on Monday, June 13, in San Diego, California.
It was last month when the Lotte Group revealed its plans to inject KRW2.5 trillion to expand its bio ventures over the next 10 years. Its biggest goal for this new investment is to become one of the world’s top 10 largest CDMOs or contract development and manufacturing organizations by the year 2030.
In any case, the company’s entrance into the bio-industry started with Lotte’s acquisition of Bristol Myers Squibb’s production plant in East Syracuse, New York. The company purchased it for $160 million, and this will be where Lotte is producing drugs for its CMO contracts.
Meanwhile, Lee Won Jik started working at Lotte Holdings last year as the company’s vice president of its new growth team and head of the ESG Management Innovation Office. He has more than two decades of experience in the global biologics and the pharmaceuticals business because aside from being a former executive at Samsung Biologics, he also worked at Bristol Myers Squibb and the U.S. Department of Health and Human Services.
As per the report, Lee Won Jik was not the only executive to be given a new role as Lotte also appointed Ha Jong Su, the company’s VP of global logistics SCM business unit, as the new inside director while Lee Hong Gi, Lotte’s healthcare unit chief, becomes the non-executive director.
